文献速递神经肿瘤

曲贝替定治疗复发WHO 2或3级脑膜瘤:EORTC脑肿瘤组随机II期研究

Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
PubMed 文献 · Neuro Oncol · 2022-01-01

该随机多中心开放标签II期研究纳入复发WHO 2或3级脑膜瘤成人患者,2:1随机分配至曲贝替定组或局部标准治疗组,主要终点为无进展生存期。结果显示曲贝替定未改善PFS和OS,且毒性更高;肿瘤DNA甲基化分类是OS的独立预后因素。

要点

  • 曲贝替定对比局部标准治疗未改善复发非良性脑膜瘤的PFS和OS。
  • 曲贝替定组≥3级不良事件发生率高于局部标准治疗组。
  • 肿瘤DNA甲基化分类是总生存期的独立预后因素。

核心结论

  • 曲贝替定未改善复发WHO 2或3级脑膜瘤患者的PFS和OS,且毒性高于局部标准治疗。
  • 肿瘤DNA甲基化分类是总生存期的独立预后因素。

研究设计与样本

  • 随机、多中心、开放标签、II期研究,纳入复发WHO 2或3级脑膜瘤成人患者。
  • 患者按2:1随机分配至静脉曲贝替定(1.5 mg/m2,每3周一次)或局部标准治疗。
  • 主要终点为无进展生存期(PFS)。
  • 次要终点包括总生存期(OS)、客观影像学缓解、安全性、生活质量(QLQ-C30和QLQ-BN20问卷)及组织探索性分子分析。

主要发现

  • PFS-6率:局部标准治疗组29.1%(95%CI 11.9%-48.8%),曲贝替定组21.1%(95%CI 11.3%-32.9%)。
  • ≥3级不良事件发生率:局部标准治疗组44.4%,曲贝替定组59%。

关键数值与推荐

  • 曲贝替定给药方案为1.5 mg/m2静脉注射,每3周一次。
  • DNA甲基化分类、体能状态、存在相关合并症、使用类固醇及基线右侧半球受累与OS独立相关。

临床怎么用

  • 曲贝替定不推荐用于复发WHO 2或3级脑膜瘤的全身治疗。
  • 肿瘤DNA甲基化分类可用于预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No systemic treatment has been established for meningioma progressing after local therapies. METHODS: This randomized, multicenter, open-label, phase II study included adult patients with recurrent WHO grade 2 or 3 meningioma. Patients were 2:1 randomly assigned to intravenous trabectedin (1.5 mg/m2 every 3 weeks) or local standard of care (LOC). The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall survival (OS), objective radiological response, safety, quality of life (QoL) assessment using the QLQ-C30 and QLQ-BN20 questionnaires, and we performed tissue-based exploratory molecular analyses. RESULTS: Ninety patients were randomized (n = 29 in LOC, n = 61 in trabectedin arm). With 71 events, median PFS was 4.17 months in the LOC and 2.43 months in the trabectedin arm (hazard ratio [HR] = 1.42; 80% CI, 1.00-2.03; P = .294) with a PFS-6 rate of 29.1% (95% CI, 11.9%-48.8%) and 21.1% (95% CI, 11.3%-32.9%), respectively. Median OS was 10.61 months in the LOC and 11.37 months in the trabectedin arm (HR = 0.98; 95% CI, 0.54-1.76; P = .94). Grade ≥3 adverse events occurred in 44.4% of patients in the LOC and 59% of patients in the trabectedin arm. Enrolled patients had impeded global QoL and overall functionality and high fatigue before initiation of systemic therapy. DNA methylation class, performance status, presence of a relevant co-morbidity, steroid use, and right hemisphere involvement at baseline were independently associated with OS. CONCLUSIONS: Trabectedin did not improve PFS and OS and was associated with higher toxicity than LOC treatment in patients with non-benign meningioma. Tumor DNA methylation class is an independent prognostic factor for OS.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Preusser M, Silvani A, Le Rhun E, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 2022. PMID: 34672349. doi:10.1093/neuonc/noab243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。